The amount of time allowed for pharmaceutical companies to have exclusive rights to the clinical data for biological drugs has been the last major sticking point in the Trans-Pacific Partnership talks in Atlanta.

The compromise under discussion would grant a data exclusivity period that would be eight years, in effect, Kyodo reported. That would be in line with a U.S. proposal from last week. Reuters could not immediately confirm the report.

(Reporting by Kevin Krolicki)